The Effect of Ligustrazine on the Lipid Peroxidation of the Hepatic Fibrosis in Rats

  • Peng Xiao
Keywords: Ligustrazine, Hepatic Fibrosis, Lipid Peroxidation, Tetramethylpyrazine


To investigate the effect of ligustrazine on lipid peroxidation of hepatic fibrosis in rats. In this experimental, it
applied subcutaneous injection of 60%CCl4 (0.3mL / 100g body weight, every two weeks) to induce hepatic
fibrosis in rats for 12 weeks. On the 1st and 31st days after the injection of CCl4, tetramethylpyrazine (TMP)
were administered in the way of the tube feeding (10mg/100μg per day) in the TMP prevention and treatment
groups, respectively. And RT-PCR and Western blot were applied to detect mRNA expression of leptin, OB-Rb,
TGF-β1 and TGF-βRII in the liver and the Smad3 and Smad7 proteins, respectively. The result indicated that the
tetramethylpyrazine (TMP) improved the liver histological structure of the hepatic fibrosis in rats, decreased
liver enzyme levels and attenuated the collagen deposition. Moreover, it was found that TMP obviously
protected the liver from the CCl4-induced damage and the fibrogenesis by inhibiting inflammation and lowering
the level of inflammatory cytokines, in which the lowered inflammatory factors included tumor necrosis factor
-a (TNF- a), NLRP3, nuclear factor- κB (NF-jB) and interleukin-1b (IL-1b). It was shown in the in vitro
experiment that TMP inhibited the expression of inflammatory cytokines in HSC, which is in connection to the
disruption of the platelet-derived growth factor b receptor (PDGF-bR) / NLRP3 / caspase1 pathway. It can be
concluded that TMP could alleviate the liver inflammation in the hepatic fibrosis and may target HSC by
passing PDGF-bR / NLRP3 / caspase1 pathways.